National Comprehensive Cancer Network

About NCCN

NCCN Guidelines and Compendium Updated

Flash Update Sent June 27, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer. These NCCN Guidelines® are currently available as Version 1.2013.

  • Small Cell Lung Cancer (SCLC)
    • For patients with clinical stage T1-2, N0 disease, the following footnotes were added: "Pathologic mediastinal staging is not required if the patient is not a candidate for surgical resection or if non-surgical treatment is pursued." "Select patients may be treated with chemotherapy/RT as an alternative to surgical resection."
    • "Primary Progressive Disease" was added to Relapse and now has the same treatment recommendations. Performance status was added after "Relapse or primary progressive disease". For patients with performance status (PS) 0-2, a category 1 designation was added to subsequent chemotherapy.
    • In the Principles of Chemotherapy section, temozolomide 75 mg/m2/day x 21 days was added to relapse ‹ 2-3 mo and relapse › 2-3 mo up to 6 mo.
    • Principles of Radiation Therapy extensively revised and updated (especially prophylactic brain irradiation [PCI]), including the addition of a section for brain metastases.
    • Principles of Supportive Care was revised:
      • "Conivaptan and tolvaptan" were added as treatment options for select patients with the syndrome of inappropriate antidiuretic hormone (SIADH).
      • "Metyrapone" was added as a treatment option for select patients with Cushing's syndrome in whom ketoconazole is not effective.
  • Lung Neuroendocrine Tumors (LNTs)
    • "Cisplatin/etoposide ± RT" was added as a primary treatment option for select patients with stage IIIB disease.
    • "Consider octreotide (including long-acting release [LAR])" was added as a primary treatment option for select patients with stage IIIB or IV disease.


For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.